<< Bisphosphonate treatments may affect bone quality and increase risk of atypical fractures of femur | Antibiotics lower risk of developing gastric cancer >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | العربية | Nederlands | Русский | Svenska | Polski

St. Jude Medical to exhibit cardiac clinical solution products portfolio at ACC 2010

Published on March 12, 2010 at 8:47 AM · No Comments

St. Jude Medical, Inc. (NYSE:STJ) today announced it will display products and technologies from the company’s wide array of clinical solutions in the cardiology, cardiac surgery, atrial fibrillation and cardiac rhythm management markets at ACC 2010.

“We offer a full range of products and technologies from across the company designed to decrease hospitalizations, improve patient quality of life and reduce healthcare costs.”

“St. Jude Medical is pleased to showcase our latest cardiac care solutions, from technologies that help to better connect patients to physicians, to devices proven to improve patient outcomes,” said Frank Callaghan, president of the St. Jude Medical Cardiovascular Division. “We offer a full range of products and technologies from across the company designed to decrease hospitalizations, improve patient quality of life and reduce healthcare costs.”

Products and technologies will be on display at St. Jude Medical booth 718 during the American College of Cardiology (ACC) Conference at the Georgia World Congress Center on Sunday, March 14, 9 a.m. - 4:30 p.m., Monday, March 15, 9 a.m. - 4:30 p.m. and Tuesday, March 16, 9 a.m. - 1 p.m., including:

Cardiovascular Division

  • Engage™ Family of Introducers: This new product line was designed to provide physicians with reliable access and set the stage for closure using the Angio-Seal™ device. The Engage™ Introducer is used for femoral access, in which physicians access the patient’s heart through the femoral vein or artery located near the groin. The Engage TR™ Introducer portfolio expands the company’s product offering to include introducers used for radial access, in which physicians access the patient’s heart through the radial artery in the arm. The Engage Introducers have received FDA clearance and CE Mark approval.
  • PressureWire™ technology: The landmark FAME (Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation) study compared FFR-guided treatment using a St. Jude Medical PressureWire to treatment using standard angiography alone, and found both superior clinical outcomes and reduced healthcare costs in patients whose treatment was based on FFR. The next generation of PressureWire™ Certus is the only guidewire on the market to offer in one wire the combined measurement of pressure and temperature which enables calculations of FFR, Coronary Flow Reserve (CFR) and an Index of Microcirculatory Resistance (IMR). The PressureWire™ Aeris is a first-of-its-kind wireless FFR measuring system requiring no additional equipment or cabling and gives physicians instant access to patient data; it can be used with multiple recording systems including the GE Mac-Lab® Hemodynamic Recording System, Mennen Horizon XVu and the McKesson Horizon Cardiology Hemo™ solution. Both products have FDA clearance and CE Mark approval.
  • Other Interventional Cardiology and Cardiac Surgery Products on Display: Epic™ Stented Tissue Valves with Linx AC Technology, Biocor™ Stented Tissue Valves, Attune™ Flexible Adjustable Annuloplasty Ring, and Regent™ Mechanical Heart Valve.

Atrial Fibrillation Division

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading